Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.
about
Effect of a cellulose acetate phthalate topical cream on vaginal transmission of simian immunodeficiency virus in rhesus monkeysA human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolatesAcute mucosal pathogenesis of feline immunodeficiency virus is independent of viral dose in vaginally infected cats.Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaquesRhesus macaque resistance to mucosal simian immunodeficiency virus infection is associated with a postentry block in viral replication.Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.Determinants of protection among HIV‐exposed seronegative persons: an overview.Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting.Prospects for oral replicating adenovirus-vectored vaccines.Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus VaccinesReplicating adenovirus vector prime/protein boost strategies for HIV vaccine development
P2860
Q33595164-4C2E1C4C-DE6A-4142-A874-AA25AF4A1BF9Q33603494-502FB4B2-9727-4BD8-8FBB-F5CD2ED3A064Q33715758-756B6715-5B77-4641-ADA0-916283540125Q34228494-C467DA4D-5DC4-47A6-8BD7-2A7491652F30Q34339609-D24739C0-5A64-4A0C-B05E-F76D3A862F65Q34651604-F9B37DEE-3D78-4CC3-B0CF-DB47C40F544DQ35155380-E0C70E60-6ACE-41CA-8E43-0C54BB0FCACCQ35182076-314D4576-1821-4131-B6D5-C5876248DCDAQ35252566-E1A39DD5-ADBC-4998-AB71-5530577BEE8EQ36954239-FA48A066-38F5-4F06-816E-5C8089F00EBDQ38109356-134CAB45-711E-4BCA-834B-71876F093DE0Q39582556-68D22723-DE6E-4BD7-BBF0-CB1718CE3E6BQ56993265-B9098CF2-21A5-4303-8D42-2E9C7C325DAA
P2860
Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Factors associated with slow d ...... nged vaginally with SIVmac251.
@ast
Factors associated with slow d ...... nged vaginally with SIVmac251.
@en
type
label
Factors associated with slow d ...... nged vaginally with SIVmac251.
@ast
Factors associated with slow d ...... nged vaginally with SIVmac251.
@en
prefLabel
Factors associated with slow d ...... nged vaginally with SIVmac251.
@ast
Factors associated with slow d ...... nged vaginally with SIVmac251.
@en
P2093
P2860
P921
P1433
P1476
Factors associated with slow d ...... enged vaginally with SIVmac251
@en
P2093
C J Miller
E S Richardson
L J Patterson
M Robert-Guroff
P D Markham
P2860
P304
P577
1999-09-01T00:00:00Z